Search

News Quality of Life of Hemophiliacs and Ways to Improve It

Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.

Source: Hemophilia with Movement 21. 5. 2021

News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles

The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.

Source: Multiple Sclerosis 18. 11. 2020

News Rurioctocog Alfa Pegol vs. Non-factor Therapy –⁠ Report from Real Clinical Practice

The standard treatment for hemophilia A is the prophylactic administration of coagulation factor VIII (FVIII) concentrate. Recently, some hemophiliacs have also been switched to prophylaxis with so-called non-factor therapy, specifically emicizumab. A recently published report from the USA shows a comparison of these two modalities in real clinical practice.

Source: Hemophilia 8. 11. 2022

News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?

The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?

Source: Multiple Sclerosis 17. 12. 2020

News Dupilumab in the Treatment of Severe Asthma in Real-World Practice

A freshly published French study is the first to confirm the results of clinical trials with dupilumab in patients with severe asthma in real-world practice.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 20. 10. 2020

News What Response to the COVID-19 Vaccine Can Be Expected in Patients After Stem Cell Transplantation?

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).

Source: Hematologic Malignancies 27. 4. 2022

News Epidemiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure in Patients with Diabetes

The proven benefit of one class of antidiabetic drugs –⁠ sodium-glucose cotransporter 2 inhibitors (SGLT2i; gliflozins) –⁠ in treating heart failure irrespective of diabetes presence, and their inclusion in therapeutic recommendations for heart failure with reduced ejection fraction of the left ventricle, brings to light unresolved questions regarding the link between diabetes and heart failure. A recently published article summarizes the current knowledge on the epidemiology and pathophysiological connection of these two diseases, as well as the current recommended diagnosis and treatment.

Source: Cardiovascular Continuum 18. 11. 2021

News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?

Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.

Source: Arthritis 9. 7. 2020

News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice

At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.

Source: Intestinal Inflammations 20. 9. 2023

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.

Source: Thromboprophylaxis 28. 11. 2023

News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function -⁠ Findings from a Recent Meta-analysis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.

Source: Heart Failure 3. 11. 2022

News Romiplostim in Newly Diagnosed or Persistent ITP

Thrombopoietin receptor agonists (TPO-RA) are now recommended for patients with newly diagnosed immune thrombocytopenia (ITP) or persistent ITP who have failed treatment with corticosteroids or intravenous immunoglobulins. The rationale for these recommendations is documented in a paper whose authors focus on, among other things, the American Society of Hematology (ASH) 2019 guidelines or the European ITP Working Group guidelines. They also summarized published data from clinical trials, real-world practice, etc., regarding the use of the TPO-RA romiplostim in earlier phases of ITP therapy.

Source: Immune Thrombocytopenia 21. 2. 2023

News Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer

Antibodies against the programmed cell death protein 1 (PD-1) improve the survival of patients with advanced non-small cell lung cancer (NSCLC). However, their use has not yet been tested in patients with resectable NSCLC. In 2018, the New England Journal of Medicine published the results of a pilot study of neoadjuvant therapy with nivolumab in patients with resectable NSCLC. Based on the promising results of this study, the investigative team subsequently decided to also test a combination of nivolumab and ipilimumab.

Source: Immunotherapy in Oncology 6. 11. 2020

News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.

Source: Oncological Treatment 22. 11. 2021

News Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients

Energy intake and the composition of individual macronutrients in patients in intensive care units (ICUs) can influence treatment outcomes in terms of the incidence of complications, duration of mechanical ventilation, or mortality.

Source: Parenteral Nutrition 14. 11. 2022